Rx vs. M&A Fees: Who Wins?

I'm curious as to which group generates more fees on average? Do top Rx groups outpace average M&A groups in fees, or M&A still tends to win? Given that M&A deals are usually larger, I would think they are ahead, but since so many restructurings are out of court it's not always easy to understand the fees generated. 

Separate question, what is a typical fee structure for an Rx group that is advising a group of lenders? Thanks for all insight!

28 Comments
 

wrong question

(deleted the fees part because of inconsistencies)

it's wrong because you're missing that there is a +20:1 ratio in terms of times when a financial advisor is involved in M&A deals vs. restructuring, so even if the average M&A might be paid a bit less, the fact that there are x20 deals means that you make way more in revenue from a business standpoint, so it's more profitable overall

But on RX, in general, if you are interested in this path as a career, forget about banking, look at fees for other advisors: 

  • Lehman: $500m Weil, Gotshal (legal), A&M $500m (consultants)
  • Caesars: $100m Kirkland (legal)
  • Enron: +$150 Weil, Gotshal 

so I get that there's some obessison about RX because of exit opportunities, but if you really live and breathe restructuring/bankruptcy, then consulting/Kirkland is the place to be because they dominate this side of business

incentives trumph ethics
 

This is very helpful and you definitely read part of my mind in terms of what I am thinking for a career in banking. I'm honestly not super clear on the main differences between Rx consulting and banking so I'm sure I should find some threads on those. 

In terms of the economics at the bank level, couldn't some groups still have MDs paid higher in Rx rather than M&A if the groups are smaller? I know that the amount they are smaller doesn't make up for the +20:1 ratio of deals, but does that bridge the gap a bit?

 
Most Helpful

Given how popular RX consulting has been recently, you'll find plenty of posts on the CO forum and the IB forum about the topic. For people who r too lazy to go search though, in a nutshell...

RX consultants:  r the hands-on operators and financial mechanics. They jump into the company itself and help it fix its internal mess, stuff lk running out of cash, bad ops, messed up fincials, etc. They might actually take interim roles like CFO or Chief Restructuring Officer (CRO), and help stabilize the business, forecast cash flow, create turnaround plans, and run cost-cutting initiatives.

They also help creditors (like lenders or bondholders) by digging into the company’s numbers, verifying if the company’s forecasts are legit, figuring out what kind of recovery the creditors can expect, etc (this is more akin to RX IB...a fair amt of RX IB knowledge is needed for RX consultants, esp the ones on creditor engagements).But overall, they’re in the weeds. Think financial triage + operational fixers. They also set the overall plan, that the RX bankers on the deal follow.

RX IB: focused on the deal side — advising either the company or creditors on capital structure solutions (debt exchanges, DIP financing, Chapter 11 plans, etc.). Their job is to craft and negotiate deals between all the stakeholders (equity holders, lenders, unsecured creditors, etc.). They’ll model out recoveries, value the business, and run the restructuring transaction kinda like M&A bankers, but for distressed companies.

They’re not running the company or fixing ops, they’re strategic advisors focused on the financial engineering and negotiation process.

*If you go look at the Deal's or similar RX league tables, you'll see that the RX consultant are usually on more $$ deals than RX IB, reason being that not all restructurings need bankers / dedicated RX IB firms. Sometimes the consultants themselves play the part of the bankers, or no bankers are brought in at all. Dedicated firms are brought in when there's better sense in hiring a specialized RX IB firm rather than let the consultants do it. Also in response to the above comment, yeah consulting / kirkland dominates the space, but imo the work they do is also more fun / interesting.

 

If you live and breathe restructuring you obviously want to do banking not law/consulting because banking is actual financial restructuring. If you love looking at capital structures, waterfalls and thinking of creative debt solutions you aren't going to want to start working on operations of a company or drafting legal docs lol 

Also looking at total fees on select deals isn't useful (especially when consultants stay for years after the Bk working with the client whereas bankers just work on the deal). Overall Rx banking comps better than rx consulting/law at junior/mid levels. Probably more equalised with law at senior level.

 

Analyst 1 in PE - LBOs

If you live and breathe restructuring you obviously want to do banking not law/consulting because banking is actual financial restructuring. If you love looking at capital structures, waterfalls and thinking of creative debt solutions you aren't going to want to start working on operations of a company or drafting legal docs lol 

Also looking at total fees on select deals isn't useful (especially when consultants stay for years after the Bk working with the client whereas bankers just work on the deal). Overall Rx banking comps better than rx consulting/law at junior/mid levels. Probably more equalised with law at senior level.

What lol, banking isn't the one and only restructuring, I'd argue it's the least impactful of the three bc the whole point of a RX process is to make sure the company can operate going into the future, and bankers don't do that, they also aren’t fixing broken ops or sitting in war rooms with management. Lawyers and consultants do. Matter of fact, bankers can't even get deals done without lawyers. In the grand scheme of things though, they're all "real" RX, so just pick ur flavor. In general, the stuff RX bankers do is a very small (and narrow) part of the actual process, so if you actually enjoy restructuring, banking isn't the place to be.

 

then got the wrong fees given by the google search AI, didn't look the docs, just removed altogether the part because doens't help the general message

incentives trumph ethics
 

I believe the exact opposite of what you said re: volume vs fee % is true haha

That or its a poor read by me - often RX is higher volume and lower % fee

 

I’d argue M&A has more variance than RX. M&A you have the guys at the low end shops scrapping to clear 1M a year and the ultra EB rainmakers getting paid 40M+, while RX there’s really only a few elite shops that do it. At the especially lean firms seniors are getting paid big time 20M+ but low end probably higher than low end M&A.

Just my two cents from what I’ve seen at my EB

 

CEOs are not the ones generating revenue... Same thing for Investment Banks. DJ Sol makes ~$30M/y, but every year there is a couple articles about some GS trader making 80M that year because whatever coverage universe he is in was super volatile and he was on the right side of it. I.e. Name Officers does not always equal highest paid in the company.

Ex: https://www.bloomberg.com/news/articles/2023-12-12/goldman-trader-who-was-paid-100-million-since-2020-to-step-down

(i remember seeing some more extreme cases, but couldnt care enough to spend more time finding them)

 

Worked in RX. Your typical fee on an RX deal ranges from $5mm - $20ish; varies based on if you’re creditor side (lower side of fees) or debtor side (higher end) and whether the deal is in court or out of court, with in court typically generating more fees (although newer LM Engagement letters have started incorporating things that track to discount capture, making them a bit more lucrative).

Comparing RX vs M&A fees is hard because RX deals will never have a gangbusters $50mm deal, but can consistently grind out 15-20 deals averaging $10mm on super lean deal teams (part of the reason some M&A analysts leave banking with no deals while RX analysts usually leave w 2-3); net result is usually higher fee per head for RX than M&A counterparts

 

This is super helpful, thanks for the insight. 15-20 deals at $10m average is still pretty crazy. Given that EB Rx teams don’t have nearly as many MDs as other groups, it sounds like they’re getting pretty good comp on average. I would definitely appreciate more insight into newer fee structures for LMEs if possible!

 

LMEs often involve some sort of discounted exchange. A lot of company-side ELs will have 25bps exchange fee, in addition to financing fees, rather than a fixed restructuring fee (although you can kind of imply one from the other and vice versa anyways)

Just by way of example for a [$2bn] LM exchange and [$250mm] super senior new money raise you might get the following:

[6 months] x $150k monthly retainer = $600k

Exchange: [50bps] x $2bn = $10mm

New Money: [100bps] x $250mm = $2.5mm

Total: $13.1mm

This is probably on the lighter end for a transaction of this size (should probably be closer to $20mm) but should give an idea. 

However, lot of sponsors / lenders have been pushing back on banker fees recently given how frequent / expensive it's getting. Banker fees tend to be relatively bigger $ out of court since there's less lawyer work whereas in court deals are really where the law firms really suck the estate dry.

 

I would assume that changes based on the type of bank, no? If GS helps a company raise capital and then that same company comes back to GS to their M&A team for a merger I can see the capital markets team wanting to get a piece of that, but that exact analogy doesn't happen at EBs as often.

 

Quasi error excepturi nam culpa veniam. Dolores esse assumenda molestiae libero. Sed et labore suscipit quasi tempora autem tenetur. Eligendi blanditiis velit ex. Est corrupti et accusamus quasi et fugiat sed. Ipsum repellat eius officia omnis delectus.

Nobis aut itaque molestiae delectus tenetur earum. Voluptatem quibusdam cum at velit ratione. Impedit dolor doloremque quisquam quam doloremque quas.

 

Mollitia dolor consectetur omnis quae qui et voluptate. Omnis voluptatum omnis aut et. Nesciunt magni rerum aut eius. Quia ducimus molestiae quod aut vero aut. Enim explicabo aliquam et eum magni.

Sint vel expedita ullam. Accusamus aperiam animi accusantium dolores ratione. Vel dicta sunt fuga dolorum optio aut velit.

Qui eius blanditiis mollitia autem magni ea laudantium. Id odio vitae distinctio voluptas ea. Autem quo aut non et voluptas corporis qui.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 02 98.8%
  • Evercore 01 98.3%
  • BMO Capital Markets 12 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 05 98.3%
  • JPMorgan No 97.7%
  • Goldman Sachs 02 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (44) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (79) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
Betsy Massar's picture
Betsy Massar
98.9
6
dosk17's picture
dosk17
98.9
7
DrApeman's picture
DrApeman
98.9
8
GameTheory's picture
GameTheory
98.9
9
CompBanker's picture
CompBanker
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”